CHOP versus m-BACOD in Non-Hodgkin's Lymphoma

W. Hryniuk, L. I. Gordon, D. Harrington, J. Andersen

Research output: Contribution to journalLetterpeer-review

1 Scopus citations


To the Editor: The results of a randomized trial reported by Gordon et al. (Nov. 5 issue)1 indicate that a chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and one containing bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin (m-BACOD) were equivalent in their activity against diffuse advanced non-Hodgkin's lymphoma but that m-BACOD was more toxic. The authors stated that “the normalized dose intensity with CHOP was higher than that with m-BACOD… even though the prescribed doses of both cyclophosphamide and doxorubicin were higher in the CHOP regimen.” Although the authors then state that “the actual…

Original languageEnglish (US)
Number of pages1
JournalNew England Journal of Medicine
Issue number8
StatePublished - Feb 25 1993

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'CHOP versus m-BACOD in Non-Hodgkin's Lymphoma'. Together they form a unique fingerprint.

Cite this